卵巢恶性肿瘤DNA倍体及其异质性的临床预后意义  

Prognostic Signification of DNA Ploid and Heterogeneity of DNA Content in Malignant Ovarian Tumors

作　　者：彭素蓉[1] 周振英[1] 陈小祥[1] 

机构地区：[1]江苏省肿瘤防治研究所妇瘤科,210009

出　　处：《实用癌症杂志》2002年第1期42-44,共3页The Practical Journal of Cancer

基　　金：江苏省科技厅社会发展基金项目资助 (No .BS2 0 0 0 0 69)

摘　　要：目的　探讨卵巢恶性肿瘤DNA倍体、异倍体和异质性与临床预后的关系。方法　应用FCM流式细胞术 ,对 2 0例卵巢恶性肿瘤、2 0例卵巢良性肿瘤、10例正常卵巢组织进行了DNA倍体、异倍体和异质性的检测 ,并分析其与临床预后的关系。结果　卵巢恶性肿瘤DNA异倍体、异质性的患者术后肿瘤复发率、死亡率明显高于卵巢恶性肿瘤DNA二倍体、同质性患者 (P <0 .0 1)。卵巢恶性肿瘤DNA二倍体、同质性患者术后无瘤生存期明显长于卵巢恶性肿瘤DNA异倍体、异质性的患者 (P <0 .0 1)。结论　卵巢恶性肿瘤DNA倍体。Objective To study the relation of DNA ploid,aneuploid,heterogeneity of DNA content in malignant ovarian tumors to clinical prognosis.Methods The samples from 20 malignant ovarinan tumors,and 20 benign tumors and from 10 normal ovaries were tested for DNA ploid,aneuploid,heterogeneity by flow cytometry,and its relation to clinical prognosis was analyzed.Results Relapse and death rates in patients with aneuploid and heterogeneity of DNA content after operation were higher than that in patients with diploid and homogeneity of DNA content( P <0.01).Free tumors survival time was longer in patients with diploid and homogeneity of DNA content( P <0.01).Conclusion DNA ploid,aneuploid and heterogeneity of DNA content in malignant ovarian tumors are significant marks of prognosis.

关 键 词：流式细胞术 DNA倍体 异质性 卵巢恶性肿瘤 卵巢肿瘤 临床 预后 

分 类 号：R737.31[医药卫生—肿瘤]